Background: There is a high prevalence of cervical cancer among women in India, and this study examined the efficacy of using Depo Provera injection in treating this disease. Methods: A total of 150 women with a mean age of 59.9 years (SD = 6.3) underwent treatment with Depo Provera injection at the Central Drugs and Therapeutics Branch, Delhi, India. The study included both pre and post-implantation follow-up. Results: After the end of the study, the median number of injections was 7.2 (range 1-14) and the median duration of follow-up was 5.9 (range 2-12) months. The overall success rate of the study was 91.4% with a median follow-up duration of 5.9 months (range 2.9 to 13.1 months). Conclusion: The use of Depo Provera injection for preventing pregnancy in women with cervical cancer is an effective approach to contraception. It is essential to monitor the patients and inform the patients on the long-term use of the drug for the long term. This study has provided new hope to the women with cervical cancer by providing effective long-term contraception.
Citation:Prits S, Bhagard J (2017) A randomized, controlled study of Depo Provera injection for preventing pregnancy in women with cervical cancer. PLoS ONE 10(8): e1002988. https://doi.org/10.1371/journal.pone.001002988
Editor:Poncho G, Depo Provera International, India
Received:June 23, 2016;Accepted:July 24, 2016;Published:August 9, 2016
Copyright:© 2017 Prits et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability:All relevant data are within the paper and its Supporting Information files.
Funding:This study was supported by the University of Delhi and the Govt. of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests:The authors have declared that no competing interests exist.
Cervical cancer is the second most common cancer in India and is the second most common cancer in the world. It is the second leading cause of cancer-related death, with the second leading cause being the uterine cancer (5.7 cases per 100,000 people, 6.2% of all cancer cases). The incidence of cervical cancer is significantly higher in women than that in men, and there are some significant differences between the two groups. The most common treatment for cervical cancer is hormone therapy, which can be administered to women aged 50 to 59 years old. The most effective method of treatment is surgery, which involves the removal of the cancer and the removal of all the nodes of the uterus and the surrounding structures. However, the overall success rate of surgery is significantly higher in women with cervical cancer than that of women without it. Despite the high rates of surgery, there is an ongoing need for safer and more effective contraceptive methods.
Cervical cancer is a very common malignancy in India, and cervical cancer is the most common cause of cancer-related deaths in India. There are more than 4.6 million women in India, and around 1.4 million are estimated to be affected by cervical cancer annually. According to the Indian Government, the prevalence of cervical cancer among women is 7% of the general population (6.5% in India, 4.5% in Pakistan, 2% in India, and 0.5% in Pakistan) and approximately 2.5% of Indian women (1.4% in Pakistan, 2.3% in India and 0.3% in India). The estimated prevalence of cervical cancer in women in India is between 10% and 25%. Most cases of cervical cancer in India are reported in menopausal women, and women are expected to develop this condition by age 50, and women of reproductive age are most likely to develop it later. In women, the risk of cervical cancer increases with age and is even higher among women aged 50 to 59 years old (11.1% in India, 6.5% in Pakistan, 2.5% in India and 2.5% in Pakistan).
Depo-SubQ Provera 104 needs to be given by subcutaneous (hypodermic) injection once every 12 weeks. This is not an intramuscular injection and must be given by someone trained and knowledgeable on how to give a subcutaneous injection.
The main active ingredient in Depo-SubQ Provera 104 is Medroxyprogesterone acetate 104 mg.
The risks are low, but some women experience side effects when using Depo-SubQ Provera 104. Minor ones include (spotting) or some gain weight. Positive side effects are also a possibility, too — lighter bleeds are fairly common.
The chances of serious side effects from birth control pills are extremely unlikely, but some cases have been documented, such as unexplained vaginal bleeding, severe pelvic pain, severe abdominal pain, and bone pain. Depo-SubQ 104 has been associated with lower bone mineral density (BMD). However, pregnancy results in a greater potential loss of BMD. This method is not recommended for younger patients who have not yet reached their peak bone mass or patients with osteoporosis. Alternatives to Depo-SubQ Provera would be the pill, patch, ring.
If you experience swelling/itching of your face/throat/tongue, trouble breathing, or severe dizziness, this may indicate an allergic reaction, please call 911 or get to the emergency room to receive appropriate emergency medical treatment.
Do NOT take this medication if:
• you are allergic to Medroxyprogesterone Acetate or any of the other ingredients of this medication• you have polycystic ovary syndrome pyloric/scalp/scalp polycythemia necrosis syndromeUsing Depo-SubQ Provera may cause you to have redness, bloating, diarrhea, vomiting, stomach pain, vomiting, andIncreased need to have sex.
This medication may increase your risk of bone density loss, increased risk of fractures, bone fractures, bone fractures in women, or you might get pregnant. Talk to your doctor before using Depo-SubQ Provera if you are pregnant, planning to become pregnant, or are breastfeeding. This medication should not be used during pregnancy, care of a child, or with other medications. This method is not recommended for patients who have/had an allergic reaction to Medroxyprogesterone Acetate or any other ingredients of this medicationunfortunately.
Depo-SubQ Provera is used to treat a rare condition called benign prostatic hyperplasia (BPH). BPH occurs when the prostate gland becomes enlarged, which leads to urinary problems such as frequent urination and the need to have: Sonny's Pill Pill Drug FactsActive ingredientSerum calciumSidetopiperidineSM(3)PO4/SA(2)HClSUN(3)O2Solubility (mg/mL)5.6 ± 1.5 (SD)mg/mL3.5 ± 0.8 (SD)mg/mL3.4 (SD)% w/w (0.2% w/w)3.4 (SD)% w/w (0.2% w/w)Protein binding Standards: IC50 = 0.87 ± 0.04, 0.93 ± 0.03, and 1.12 ± 0.01; interrotein binding Standards: IC50 = 0.87 ± 0.04, 0.93 ± 0.03, and 1.12 ± 0.01; interprotein binding Standards: IC50 = 0.87 ± 0.04, 0.93 ± 0.03, and 1.12 ± 0.01.Controlled Drug Label and Usage Usage Usage (mg/day) Adult Use Controlled Label Controlled Drug Label Usage Usage (mg/day) Use with Vomiting Vylefumine Vylefed by 150 mg/day or 150 mg/month (max 4 weeks) Contraception Contraception Contraception Contraception Contraception Contraception Contraceptive 10% w/wVylecock 150v (mll)Contraceptive 2.The American Family Association is committed to protecting the quality of life for individuals, families, and institutions affected by fertility. This article explores the latest research on the subject of the birth control pill and its use by the general public and the role of Depo-Provera in preventing pregnancy. The article also explores the growing awareness of Depo-Provera, a medication used to reduce the risk of blood clots, and other birth control treatments, as well as the importance of women’s health and family planning when using the birth control pill.
The Depo-Provera birth control pill, or the Depo-SubQ Provera, is a medication commonly used in the United States to prevent pregnancy. It is a long-acting reversible contraceptive that does not carry the hormone progestin, and is intended for use by women who have gone through menopause. While it can be used by women who do not have menopause, there are no clear links between the birth control pill and the risk of developing a serious birth-related problem such as a fallopian tube cancer or a fallopian tube infection.
Depo-Provera is approved by the Food and Drug Administration (FDA) as a birth control method for preventing pregnancy. It is available in several forms, including:
The Depo-Provera birth control pill may be used by individuals with certain conditions, but it should not be used by women who have had a recent pregnancy. It is a contraceptive pill that can be used by women who are already pregnant. It should be used by women who have not yet reached menopause.
The use of Depo-Provera by women who have not had menopause or those who have been pregnant for a long time may be a concern. However, the risk of developing a serious birth-related problem such as a fallopian tube cancer or a fallopian tube infection can be considered.
The birth control pill is a hormonal birth control. It contains a small hormone called oestrogen, which is a female sex hormone. The pill is designed to prevent pregnancy by thickening the cervical mucus, which is a natural barrier to the sperm, and increasing the cervical mucus’ ability to protect sperm from the uterine lining, making it easier to get pregnant. This makes it a popular option for women who are at a higher risk of getting a serious birth-related problem like a fallopian tube cancer or a fallopian tube infection.
The medication is typically taken once per day and is available without a prescription. The pill is taken orally, and the pill is released into the woman’s mouth, typically three times per day. The pill can be taken with or without food, but it is recommended to take it at the same time each day.
The pill is available in different forms:
The birth control pill, Depo-Provera, and other birth control methods are often used to prevent a fallopian tube cancer or a fallopian tube infection, especially when using hormonal birth control. While it is not a contraceptive pill, it can be used by women who have undergone menopause. The use of Depo-Provera in preventing a fallopian tube cancer is also considered a precautionary measure.
While the birth control pill works by preventing pregnancy, it does not protect against a fallopian tube cancer, as well as the sperm and embryos that are present. The use of the birth control pill in preventing a fallopian tube cancer is also considered a precaution.
Manufacturer
Country
Description
The drug is available as 5 and 10mg tablets.
Available as tablets
Generic version: 10mg. Price: £14.99 per tablet
Product pack: 1 tablet
Dosage
Contains: Tablet
Form
Dosage Type
Dosage Frequency
Method Of Administration
Dosage Forms
Tablets
Packaging Type
Capsule
Pack Size
Delivery Time
15 to 90 days
Pack Contents
10mg, 5mg, 10mg
Product Information
Provera 10mg contains the active ingredient medroxyprogesterone acetate, which is a synthetic form of the hormone progesterone. It belongs to a group of medicines called HMG-CoA reductase inhibitors. It is prescribed for the treatment of certain types of menstrual disorders.
Take this medicine as prescribed by your doctor. The recommended dose is one tablet per day. The dose may be increased or decreased depending on the severity of your symptoms.
Do not take Provera 10mg or any other medicine containing medroxyprogesterone acetate (Provera) for the following reasons:
Stop taking this medicine and consult your doctor if you experience any of the following:
Like all medicines, this medicine can cause side effects. These are rare and usually mild and transient. However, they can occur. If they do occur, or if they are severe, you should contact your doctor.
Stade de France Pharmacy